May 5 (Reuters) - Revvity RVTY.N on Tuesday lowered its annual profit and revenue forecast, as the medical equipment maker excludes its immunodiagnostics business in China that it plans to divest.

Here are the results:

• Revvity expects 2026 adjusted profit to be between $5.20 and $5.30 per share, compared with its prior view of $5.35 to $5.45 per share.

• Analysts were expecting annual profit to be $5.39 per share, according to data compiled by LSEG.

• The company said it has decided to sell its immunodiagnostics business in China, which accounted for about 6% of its total revenue in the 2025 fiscal year.

• Revvity has signed a letter of intent with a potential buyer and expects to reach a definitive agreement in the second quarter of 2026, with the transaction targeted to close in 2027, subject to regulatory approvals, the company said.

• It expects annual sales in the range of $2.81 billion to $2.84 billion, compared with its previous forecast between $2.96 billion and $2.99 billion.

• Life-sciences tools and services companies have been contending with cautious post-pandemic funding for smaller biotechs and weak academic research funding.

• The company earned quarterly adjusted profit of $1.06 per share, beating analysts' average estimate of $1.02.

• Revenue at its diagnostic unit, which provides testing tools for processes such as genetic screening, rose 8% to $349 million from a year ago.

• Revvity's life sciences unit, which provides reagents and instruments for drug discovery and development, brought in quarterly revenue of $362 million, compared with estimates of $361.2 million.